The antidiabetic drug rosiglitazone blocks Kv1.5 potassium channels in an open state
An antidiabetic drug, rosiglitazone is a member of the drug class of thiazolidinedione. Although restrictions on use due to the possibility of heart toxicity have been removed, it is still a drug that is concerned about side effects on the heart. We here examined, using Chinese hamster ovary cells,...
Saved in:
| Published in | The Korean journal of physiology & pharmacology Vol. 26; no. 2; pp. 135 - 144 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Physiological Society and The Korean Society of Pharmacology
01.03.2022
대한약리학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1226-4512 2093-3827 |
| DOI | 10.4196/kjpp.2022.26.2.135 |
Cover
| Abstract | An antidiabetic drug, rosiglitazone is a member of the drug class of thiazolidinedione. Although restrictions on use due to the possibility of heart toxicity have been removed, it is still a drug that is concerned about side effects on the heart. We here examined, using Chinese hamster ovary cells, the action of rosiglitazone on Kv1.5 channels, which is a major determinant of the duration of cardiac action potential. Rosiglitazone rapidly and reversibly inhibited Kv1.5 currents in a concentration-dependent manner (IC
= 18.9 μM) and accelerated the decay of Kv1.5 currents without modifying the activation kinetics. In addition, the deactivation of Kv1.5 current, assayed with tail current, was slowed by the drug. All of the results as well as the use-dependence of the rosiglitazone-mediated blockade indicate that rosiglitazone acts on Kv1.5 channels as an open channel blocker. This study suggests that the cardiac side effects of rosiglitazone might be mediated in part by suppression of Kv1.5 channels, and therefore, raises a concern of using the drug for diabetic therapeutics. |
|---|---|
| AbstractList | An antidiabetic drug, rosiglitazone is a member of the drug class of thiazolidinedione.
Although restrictions on use due to the possibility of heart toxicity have been removed, it is still a drug that is concerned about side effects on the heart.
We here examined, using Chinese hamster ovary cells, the action of rosiglitazone on Kv1.5 channels, which is a major determinant of the duration of cardiac action potential.
Rosiglitazone rapidly and reversibly inhibited Kv1.5 currents in a concentrationdependent manner (IC50 = 18.9 μM) and accelerated the decay of Kv1.5 currents without modifying the activation kinetics. In addition, the deactivation of Kv1.5 current, assayed with tail current, was slowed by the drug. All of the results as well as the usedependence of the rosiglitazone-mediated blockade indicate that rosiglitazone acts on Kv1.5 channels as an open channel blocker. This study suggests that the cardiac side effects of rosiglitazone might be mediated in part by suppression of Kv1.5 channels, and therefore, raises a concern of using the drug for diabetic therapeutics. KCI Citation Count: 0 An antidiabetic drug, rosiglitazone is a member of the drug class of thiazolidinedione. Although restrictions on use due to the possibility of heart toxicity have been removed, it is still a drug that is concerned about side effects on the heart. We here examined, using Chinese hamster ovary cells, the action of rosiglitazone on Kv1.5 channels, which is a major determinant of the duration of cardiac action potential. Rosiglitazone rapidly and reversibly inhibited Kv1.5 currents in a concentration-dependent manner (IC 50 = 18.9 µM) and accelerated the decay of Kv1.5 currents without modifying the activation kinetics. In addition, the deactivation of Kv1.5 current, assayed with tail current, was slowed by the drug. All of the results as well as the use-dependence of the rosiglitazone-mediated blockade indicate that rosiglitazone acts on Kv1.5 channels as an open channel blocker. This study suggests that the cardiac side effects of rosiglitazone might be mediated in part by suppression of Kv1.5 channels, and therefore, raises a concern of using the drug for diabetic therapeutics. An antidiabetic drug, rosiglitazone is a member of the drug class of thiazolidinedione. Although restrictions on use due to the possibility of heart toxicity have been removed, it is still a drug that is concerned about side effects on the heart. We here examined, using Chinese hamster ovary cells, the action of rosiglitazone on Kv1.5 channels, which is a major determinant of the duration of cardiac action potential. Rosiglitazone rapidly and reversibly inhibited Kv1.5 currents in a concentration-dependent manner (IC50 = 18.9 μM) and accelerated the decay of Kv1.5 currents without modifying the activation kinetics. In addition, the deactivation of Kv1.5 current, assayed with tail current, was slowed by the drug. All of the results as well as the use-dependence of the rosiglitazone-mediated blockade indicate that rosiglitazone acts on Kv1.5 channels as an open channel blocker. This study suggests that the cardiac side effects of rosiglitazone might be mediated in part by suppression of Kv1.5 channels, and therefore, raises a concern of using the drug for diabetic therapeutics.An antidiabetic drug, rosiglitazone is a member of the drug class of thiazolidinedione. Although restrictions on use due to the possibility of heart toxicity have been removed, it is still a drug that is concerned about side effects on the heart. We here examined, using Chinese hamster ovary cells, the action of rosiglitazone on Kv1.5 channels, which is a major determinant of the duration of cardiac action potential. Rosiglitazone rapidly and reversibly inhibited Kv1.5 currents in a concentration-dependent manner (IC50 = 18.9 μM) and accelerated the decay of Kv1.5 currents without modifying the activation kinetics. In addition, the deactivation of Kv1.5 current, assayed with tail current, was slowed by the drug. All of the results as well as the use-dependence of the rosiglitazone-mediated blockade indicate that rosiglitazone acts on Kv1.5 channels as an open channel blocker. This study suggests that the cardiac side effects of rosiglitazone might be mediated in part by suppression of Kv1.5 channels, and therefore, raises a concern of using the drug for diabetic therapeutics. An antidiabetic drug, rosiglitazone is a member of the drug class of thiazolidinedione. Although restrictions on use due to the possibility of heart toxicity have been removed, it is still a drug that is concerned about side effects on the heart. We here examined, using Chinese hamster ovary cells, the action of rosiglitazone on Kv1.5 channels, which is a major determinant of the duration of cardiac action potential. Rosiglitazone rapidly and reversibly inhibited Kv1.5 currents in a concentration-dependent manner (IC = 18.9 μM) and accelerated the decay of Kv1.5 currents without modifying the activation kinetics. In addition, the deactivation of Kv1.5 current, assayed with tail current, was slowed by the drug. All of the results as well as the use-dependence of the rosiglitazone-mediated blockade indicate that rosiglitazone acts on Kv1.5 channels as an open channel blocker. This study suggests that the cardiac side effects of rosiglitazone might be mediated in part by suppression of Kv1.5 channels, and therefore, raises a concern of using the drug for diabetic therapeutics. |
| Author | Hahn, Sang June Lee, Hyang Mi Choi, Bok Hee |
| AuthorAffiliation | 1 Department of Pharmacology, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju 54097, Korea 2 Department of Physiology, Medical Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea |
| AuthorAffiliation_xml | – name: 1 Department of Pharmacology, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju 54097, Korea – name: 2 Department of Physiology, Medical Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea |
| Author_xml | – sequence: 1 givenname: Hyang Mi surname: Lee fullname: Lee, Hyang Mi organization: Department of Pharmacology, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju 54097, Korea – sequence: 2 givenname: Sang June surname: Hahn fullname: Hahn, Sang June organization: Department of Physiology, Medical Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea – sequence: 3 givenname: Bok Hee surname: Choi fullname: Choi, Bok Hee organization: Department of Pharmacology, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju 54097, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35203063$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002815916$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9kUtr3DAUhUVJaaZp_kAXRct2YVdvS5tCCH2EBgJhuhayLM-o45FcSw4kvz5yJg1NFl1dkM75zuWet-AoxOAAeI9RzbASn3e_x7EmiJCaiJrUmPJXYEWQohWVpDkCK0yIqBjH5BicpuRbhCRHXCL1BhxTThBFgq7Aer110ITsO29al72F3TRv4BST3ww-m7uSCtsh2l2CP29wzeEYsym8eQ_t1oTghgR9KAgYRxdgyia7d-B1b4bkTh_nCfj17ev6_Ed1efX94vzssrKMilwpyTBmjVJIdKisZvry7BQTqHHYUq6s7FUnKOldw6jh0ja0RR03De0FZ4aegE8Hbph6vbNeR-Mf5ibq3aTPrtcXWinKsaJF--WgHed27zrrQp7MoMfJ7810--B8_hP8tnButJQKKcYK4OMjYIp_Zpey3vtk3TCY4OKcNBGUSiEbukg__Jv1FPL37EVADgJbDp0m1z9JMNJLvXqpVy_1Fq4mutRbTPKFyZaCso_Lvn74n_UekvWqtw |
| CitedBy_id | crossref_primary_10_3389_fphar_2024_1308217 crossref_primary_10_4196_kjpp_2023_27_1_95 |
| Cites_doi | 10.1177/0091270002250602 10.1016/S0014-2999(99)00020-5 10.1111/j.1540-8159.1994.tb01453.x 10.1161/01.RES.0000096362.60730.AE 10.1007/BF00656997 10.1016/S1570-0232(02)01011-5 10.1007/s00210-006-0118-6 10.1161/01.RES.77.3.575 10.1016/j.jchromb.2004.01.010 10.1210/rp.56.1.265 10.1161/01.RES.73.6.1061 10.1146/annurev.biochem.77.061307.091829 10.4196/kjpp.2020.24.6.545 10.2165/00003495-200262120-00007 10.1016/0896-6273(90)90146-7 10.1111/j.1476-5381.2011.01210.x 10.4196/kjpp.2016.20.2.193 10.1016/S0014-2999(01)01047-0 10.1016/S0008-6363(97)00121-1 10.1056/NEJMoa072761 10.2165/00003495-200767180-00008 10.1096/fasebj.5.3.2001794 10.1152/ajpcell.1994.267.5.C1231 10.1161/01.CIR.82.6.2235 10.1152/ajpendo.00312.2002 10.1152/physrev.1996.76.1.49 10.1161/01.RES.78.5.903 10.1161/01.CIR.94.3.562 10.4196/kjpp.2016.20.1.75 10.1007/s11892-019-1270-y 10.1038/sj.bjp.0702129 |
| ContentType | Journal Article |
| Copyright | Copyright © Korean J Physiol Pharmacol 2022 |
| Copyright_xml | – notice: Copyright © Korean J Physiol Pharmacol 2022 |
| DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
| DOI | 10.4196/kjpp.2022.26.2.135 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 2093-3827 |
| EndPage | 144 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_9935193 PMC8890944 35203063 10_4196_kjpp_2022_26_2_135 |
| Genre | Journal Article |
| GroupedDBID | --- 5-W 5GY 8JR 8XY 9ZL AAYXX ABDBF ACUHS ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK E3Z EBD EF. ESX F5P GX1 HYE MK0 OK1 P2P P5Y P6G RPM TR2 TUS NPM 7X8 5PM 53G ACYCR KVFHK |
| ID | FETCH-LOGICAL-c436t-98411479906d0058af436e94607e1c359c8f9d632fe743a58c73b0d5a73f654a3 |
| ISSN | 1226-4512 |
| IngestDate | Sun Mar 09 07:50:49 EDT 2025 Thu Aug 21 13:53:37 EDT 2025 Fri Jul 11 05:35:45 EDT 2025 Thu Apr 03 07:07:50 EDT 2025 Tue Jul 01 02:33:17 EDT 2025 Thu Apr 24 23:02:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Open channel block Rosiglitazone Kv1.5 channel Cardiotoxicity Ion channel |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c436t-98411479906d0058af436e94607e1c359c8f9d632fe743a58c73b0d5a73f654a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8890944 |
| PMID | 35203063 |
| PQID | 2633868734 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9935193 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8890944 proquest_miscellaneous_2633868734 pubmed_primary_35203063 crossref_primary_10_4196_kjpp_2022_26_2_135 crossref_citationtrail_10_4196_kjpp_2022_26_2_135 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-03-01 |
| PublicationDateYYYYMMDD | 2022-03-01 |
| PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | The Korean journal of physiology & pharmacology |
| PublicationTitleAlternate | Korean J Physiol Pharmacol |
| PublicationYear | 2022 |
| Publisher | The Korean Physiological Society and The Korean Society of Pharmacology 대한약리학회 |
| Publisher_xml | – name: The Korean Physiological Society and The Korean Society of Pharmacology – name: 대한약리학회 |
| References | ref13 ref12 ref15 ref14 ref31 ref30 ref11 ref10 ref32 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – ident: ref31 doi: 10.1177/0091270002250602 – ident: ref6 doi: 10.1016/S0014-2999(99)00020-5 – ident: ref15 doi: 10.1111/j.1540-8159.1994.tb01453.x – ident: ref30 doi: 10.1161/01.RES.0000096362.60730.AE – ident: ref18 doi: 10.1007/BF00656997 – ident: ref26 doi: 10.1016/S1570-0232(02)01011-5 – ident: ref7 doi: 10.1007/s00210-006-0118-6 – ident: ref19 doi: 10.1161/01.RES.77.3.575 – ident: ref32 doi: 10.1016/j.jchromb.2004.01.010 – ident: ref29 doi: 10.1210/rp.56.1.265 – ident: ref14 doi: 10.1161/01.RES.73.6.1061 – ident: ref28 doi: 10.1146/annurev.biochem.77.061307.091829 – ident: ref23 doi: 10.4196/kjpp.2020.24.6.545 – ident: ref2 doi: 10.2165/00003495-200262120-00007 – ident: ref17 – ident: ref16 doi: 10.1016/0896-6273(90)90146-7 – ident: ref8 doi: 10.1111/j.1476-5381.2011.01210.x – ident: ref25 doi: 10.4196/kjpp.2016.20.2.193 – ident: ref5 doi: 10.1016/S0014-2999(01)01047-0 – ident: ref20 doi: 10.1016/S0008-6363(97)00121-1 – ident: ref3 doi: 10.1056/NEJMoa072761 – ident: ref1 doi: 10.2165/00003495-200767180-00008 – ident: ref10 doi: 10.1096/fasebj.5.3.2001794 – ident: ref9 doi: 10.1152/ajpcell.1994.267.5.C1231 – ident: ref12 doi: 10.1161/01.CIR.82.6.2235 – ident: ref27 doi: 10.1152/ajpendo.00312.2002 – ident: ref11 doi: 10.1152/physrev.1996.76.1.49 – ident: ref13 doi: 10.1161/01.RES.78.5.903 – ident: ref21 doi: 10.1161/01.CIR.94.3.562 – ident: ref24 doi: 10.4196/kjpp.2016.20.1.75 – ident: ref4 doi: 10.1007/s11892-019-1270-y – ident: ref22 doi: 10.1038/sj.bjp.0702129 |
| SSID | ssib008505809 ssj0064464 |
| Score | 2.2416189 |
| Snippet | An antidiabetic drug, rosiglitazone is a member of the drug class of thiazolidinedione. Although restrictions on use due to the possibility of heart toxicity... An antidiabetic drug, rosiglitazone is a member of the drug class of thiazolidinedione. Although restrictions on use due to the possibility of heart toxicity... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 135 |
| SubjectTerms | Original 약리학 |
| Title | The antidiabetic drug rosiglitazone blocks Kv1.5 potassium channels in an open state |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35203063 https://www.proquest.com/docview/2633868734 https://pubmed.ncbi.nlm.nih.gov/PMC8890944 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002815916 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | The Korean Journal of Physiology & Pharmacology, 2022, 26(2), , pp.135-144 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELa6i4T2goDlUV4yCHGJUto4cZzjUgFlV0V76Eq9WYmbtKE0qbrNofsr-UnM2Hm1rBDsJa1c23HzfRrPTGbGhLxPHKF4kgR2EsxCG-MI7YglkS3cWejzREQhw0Th8Xc-unLPp9600_nViloqtlFP3dyaV3IXVKENcMUs2f9Atp4UGuA74AtXQBiu_4wxPJnUOFBTZc02xdyCfS-dY-3tmzzTkelqeW1dgJnqWet8C8pyWqx0wm8G-yL6O_B0inWcWTq5qK2t4vwX-aZy1peKq3aGmNJNyJt1U_y6ds-X4T2jXZjNrXHaiLmFcbdi83nRvNEfLnIdVfApX8JGGLddEWDF1rFYvSqZrVzUZbUSzbQqABVfBbQ6Vc0Y7He4VCONQTe0Xa-Ms451m9MPmM2EKShQiXCTdF9S1WnJ44GphVJu7QNTavJw13BBCgHUyx9rLGDqOD2H95xeObRFo_VK8whUVjS0WLOD1nGNl-OhEAFYzO4Ruef4vg4c-DptJKgAhVMXTDO6AiijusBZ_UdNWhcu6OOfyzkh96t772lRR9kmuc1AOozzbSlOk4fkQWnx0DND30ekE2ePyelZFm7z1Y5-oDWIu1MyAdxom9EUGU33GE0No6lmNK0ZTStG0zSDKSgymmpGPyFXXz5PhiO7PPfDVi7jWzsQLljpPuhJfIbHXoYJNMeBy_t-PFDMC5QAycKZk8Sg_4aeUD6L-jMv9FnCPTdkT8lxBut5TuhgEHnMi5XHAROfR4EXcOUEXLgqEsz1umRQPUepyqL4eDbLTwnGMcIgEQaJMEiHS0cCDF1i1WPWpiTMX3u_A3jkUqUSK7nj5zyXy40Ee_WbBOsATagueVuhJ0G84zu7MIvz4hqmYUxw4TO3S54ZNOubVmToEn8P57oD3nD_lyxd6BLyJUtf3HnkS3LSSIBX5Hi7KeLXoJ5vozea8b8Bh2vljg |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+antidiabetic+drug+rosiglitazone+blocks+Kv1.5+potassium+channels+in+an+open+state&rft.jtitle=The+Korean+journal+of+physiology+%26+pharmacology&rft.au=Lee%2C+Hyang+Mi&rft.au=Hahn%2C+Sang+June&rft.au=Choi%2C+Bok+Hee&rft.date=2022-03-01&rft.pub=The+Korean+Physiological+Society+and+The+Korean+Society+of+Pharmacology&rft.issn=1226-4512&rft.eissn=2093-3827&rft.volume=26&rft.issue=2&rft.spage=135&rft.epage=144&rft_id=info:doi/10.4196%2Fkjpp.2022.26.2.135&rft_id=info%3Apmid%2F35203063&rft.externalDocID=PMC8890944 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1226-4512&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1226-4512&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1226-4512&client=summon |